|
注册号: Registration number: |
ChiCTR2500104204 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-12 12:38:43 |
|
注册时间: Date of Registration: |
2025-06-12 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
AR眼镜在超声引导颈内静脉穿刺中的应用:一项前瞻性、随机、对照研究 |
|
Public title: |
Use of AR glasses in ultrasound-guided internal jugular vein puncture: A prospective, randomized, controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
AR眼镜在超声引导颈内静脉穿刺中的应用:一项前瞻性、随机、对照研究 |
|
Scientific title: |
Use of AR glasses in ultrasound-guided internal jugular vein puncture: A prospective, randomized, controlled study |
|
研究课题代号(代码): Study subject ID: |
24HDQYLH06 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
24HDQYLH06 |
|
申请注册联系人: |
廖咏新 |
研究负责人: |
沈宁 |
|
Applicant: |
Yongxin Liao |
Study leader: |
Shen Ning |
|
申请注册联系人电话: Applicant telephone: |
+86 10 4910 8853 |
研究负责人电话:
Study leader's |
+86 139 2220 9000 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
aggie52@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
paulshenyh@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
广州市花都区新华路48号 |
研究负责人通讯地址: |
广州市花都区新华路48号 |
|
Applicant address: |
No.48 Xinhua Road, Huadu District, Guangzhou City |
Study leader's address: |
No.48 Xinhua Road, Huadu District, Guangzhou City |
|
申请注册联系人邮政编码: Applicant postcode: |
510800 |
研究负责人邮政编码: Study leader's postcode: |
510800 |
|
申请人所在单位: |
广州市花都区人民医院 |
||
|
Applicant's institution: |
Huadu District People's Hospital of Guangzhou |
||
|
研究负责人所在单位: |
广州市花都区人民医院 |
||
|
Affiliation of the Leader: |
Huadu District People's Hospital of Guangzhou |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2024037 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
广州市花都区人民医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Medical Ethics Committee of Huadu District People's Hospital, Guangzhou |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-03-28 00:00:00 | ||
|
伦理委员会联系人: |
陈晓慧 |
||
|
Contact Name of the ethic committee: |
Chen Xiaohui |
||
|
伦理委员会联系地址: |
广州市花都区新华路48号 |
||
|
Contact Address of the ethic committee: |
No.48 Xinhua Road, Huadu District, Guangzhou City |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 20 6293 5386 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
rykjk@126.com |
|
研究实施负责(组长)单位: |
广州市花都区人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Huadu District People's Hospital of Guangzhou |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
广州市花都区新华路48号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No.48 Xinhua Road, Huadu District, Guangzhou City |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
区财政支持及研究实施单位经费支持 |
||||||||||||||||||||||
|
Source(s) of funding: |
District financial support and financial support from research implementation units |
||||||||||||||||||||||
|
研究疾病: |
循环系统疾病 |
||||||||||||||||||||||
|
Target disease: |
Circulatory diseases |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
中心静脉穿刺技术是临床上常用的穿刺技术,传统的中心静脉穿刺技术是基于识别解剖结构以及触摸静脉旁的动脉搏动来实现的。这一传统的穿刺技术并不能应对解剖变异的患者,且在血栓形成高危患者行中心静脉导管放置的过程中出现血栓脱落等风险进而对患者造成严重后。但是,超声引导下的穿刺可以很容易地看到解剖结构和确认静脉通畅,有助于避免意外的动脉穿刺。此外,在特殊的临床情况下,基于动脉脉搏触诊的标志性技术具有挑战性或不可能(例如,心肺复苏期间中心静脉导管(CVC)的放置等)。 增强现实(AR)技术的发展促进了可视化的发展,佩戴AR设备链接超声机,超声的实时影像以及现实周围环境视野将同时清晰的呈现在佩戴者的眼前。本研究主要是探讨AR技术在超声引导下穿刺等操作上的应用优势,能更好的做到手眼协调,降低穿刺操作的复杂性,降低操作时间和并发症发生率、提高操作者的满意度。 |
||||||||||||||||||||||
|
Objectives of Study: |
The central venous puncture technique is a commonly used puncture technique in clinical practice. The traditional central venous puncture technique is based on identifying anatomical structures and touching the arterial pulsation next to the vein. This traditional puncture technique cannot deal with patients with anatomical variations, and there is a risk of thrombosis during the placement of central venous catheters in patients at high risk of thrombosis. However, ultrasound-guided puncture can easily see the anatomical structure and confirm the patency of the vein, which helps to avoid accidental arterial puncture. In addition, in special clinical situations, the landmark technique based on arterial palpation is challenging or impossible (for example, the placement of central venous catheter (CVC) during cardiopulmonary resuscitation). The development of augmented reality (AR) technology has promoted the development of visualization. Wearing an AR device linked to an ultrasound machine, the real-time image of ultrasound and the surrounding environment will be clearly displayed in front of the wearer. This study mainly discusses the application advantages of AR technology in ultrasound-guided puncture and other operations, which can better achieve hand-eye coordination, reduce the complexity of puncture operations, reduce the operation time and complication rate, and improve the satisfaction of operators. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1: 穿刺部位感染、外伤、烧伤或皮肤破损等 2: 颈内静脉血栓或可疑血栓 3: 严重凝血功能障碍(INR > 1.5,血小板 < 50×10⁹/L 或近期使用抗凝药物未停药) 4: 孕妇或哺乳期妇女 |
||||||||||||||||||||||
|
Exclusion criteria: |
1: Infection at the puncture site, trauma, burns, or skin breakage, etc 2: Internal jugular vein thrombosis or suspicious thrombosis 3: Severe coagulopathy (INR > 1.5, platelets < 50×10⁹/L or recent use of anticoagulants that have not been discontinued) 4: Pregnant or lactating women |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2024-07-01 00:00:00至 To 2026-06-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-06-15 00:00:00 至 To 2025-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
简单随机法;由研究人员使用SAS、SPSS等软件产生随机数 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Simple stochastic method;Random numbers are generated by researchers using software such as SAS, SPSS, etc. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
计划于研究结束后三个月(约2026年9月)共享原始数据,可通过邮件形式向研究者获取。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data are planned to be shared three months after the end of the study (approximately September 2026) and can be obtained from the investigators by email.. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
通过电子病历系统、手术室麻醉信息系统、调查表、登记表、随访表等获取及记录所需信息,并采用Microsoft Excel、SPSS 27.0软件等进行数据录入及统计分析。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Obtain and record the required information through the electronic medical record system, operating room anesthesia information system, questionnaire, registration form, follow-up form, etc., and use Microsoft Excel, SPSS 27.0 software, etc. for data entry and statistical analysis. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |